Results 241 to 250 of about 204,414 (356)

Androgen receptor expression in human ovarian and uterine tissue of long term androgen-treated transsexual women [PDF]

, 1994
S. Chadha, Thierry D. Pache, Frans J.M. Huikeshoven, Albert O. Brinkmann, Theodorus H. van derKwast   +4 more
openalex   +1 more source

Hormone Therapy Usage Is Associated With Adverse Cardiovascular Events in Prostate Cancer Patients of the All of Us Research Program Cohort

The Prostate, EarlyView.
ABSTRACT Background Hormone therapy (HT) has greatly improved overall survival for prostate cancer patients, but may also influence cardiovascular health in an already high‐risk population. Methods This retrospective cohort study examined participants in the All of Us Research Program with prostate cancer, had no prior history of adverse cardiovascular
Yuanchu J. Yang, Chenjie Zeng, Kerry R. Schaffer, Tam C. Tran, Peter J. Sauer, Lincoln A. Brown, Ben H. Park, Joshua C. Denny   +7 more
wiley   +1 more source

Androgen receptor inhibitors in treating prostate cancer. [PDF]

Asian J Androl
Cole RN, Fang Q, Matsuoka K, Wang Z.
europepmc   +1 more source

Transcriptional regulation of androgen receptor gene expression in Sertoli cells and other cell types [PDF]

, 1992
Leen J. Blok, Axel P. N. Themmen, Antoine H.F.M. Peters, Jan Trapman, Willy M. Baarends, Jos W. Hoogerbrugge, J. Anton Grootegoed   +6 more
openalex   +1 more source

Real‐World Overall Survival Comparison of Enzalutamide and Abiraterone In First‐ and Second‐Line Setting of Metastatic Castration‐Resistant Prostate Cancer

The Prostate, EarlyView.
ABSTRACT Background While their indications overlap, no clinical trials have compared abiraterone and enzalutamide for overall survival (OS) in mCRPC. Methods A large, country‐wide health insurance database (2013‐2023) was assessed for the OS comparison between abiraterone and enzalutamide. Results Overall, 3497 patients were identified with first‐ (n =
András Horváth, Celia Blasszauer, Ida Komka, Dániel Reibl, Boris Hadaschik, Tamás Fazekas, Pawel Rajwa, Àron Soós, Anikó Valikovics, Péter Nyirády, Tibor Szarvas   +10 more
wiley   +1 more source

Small-molecule disruption of androgen receptor-dependent chromatin clusters. [PDF]

Proc Natl Acad Sci U S A
Kohrt SE, Novak EJ, Tapadar S, Wu B, Strope J, Asante Y, Kim H, Chang MS, Gurdak D, Khalil A, Rood M, Raftery E, Stavreva D, Nguyen HM, Brown LG, Ramser M, Peer C, Meyers WM, Aboreden N, Chakravortee M, Sallari R, Nelson PS, Kelly KK, Graham TGW, Darzacq X, Figg WD, Oyelere AK, Corey E, Adelaiye-Ogala R, Gryder BE.   +29 more
europepmc   +1 more source

WB2838 (3-chloro-4-(2-amino-3-chlorophenyl)-pyrrole): Non-steroidal androgen-receptor antagonist produced by a Pseudomonas.

, 1993
Yasuhiro Hori, Yukiko Abe, Hidenori Nakajima, Shigehiro Takase, Takashi Fujita, Toshio Goto, MASAKUNI OKUHARA, MASANOBU KOHSAKA   +7 more
openalex   +2 more sources

Genomic Signatures Correlating With Adverse Pathologic Features in Men Eligible for Active Surveillance

The Prostate, EarlyView.
ABSTRACT Background Genomic biomarkers offer opportunities to improve risk stratification for patients with prostate cancer. We performed a transcriptomic profile of active surveillance (AS)‐eligible patients who underwent radical prostatectomy (RP) to understand genomic associations with adverse pathologic features (APF) at RP.
Jamie Michael, Eric V. Li, Mitch Huang, Nicole Handa, Nalin Kundu, Austin Ho, Hiten D. Patel, James A. Proudfoot, Sai Kaushik Shankar Ramesh Kumar, Edward M. Schaeffer, Elai Davicioni, Ridwan Alam, Ashley E. Ross   +12 more
wiley   +1 more source

RETRACTION: Interleukin-4 Activates Androgen Receptor Through CBP/p300. [PDF]

Prostate
europepmc   +1 more source

The role of androgens and global and tissue-specific androgen receptor expression on body composition, exercise adaptation, and performance. [PDF]

Biol Sex Differ
Barsky ST, Monks DA.
europepmc   +1 more source